Cardiovascular Clinical Trials in Jacksonville, Florida

14 recruitingJacksonville, Florida

Showing 114 of 14 trials

Recruiting

Product Surveillance Registry

Cardiac Rhythm DisordersDigestive disordersMinimally Invasive Surgical Procedures+13 more
Medtronic100,000 enrolled395 locationsNCT01524276
Recruiting
Phase 3

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled95 locationsNCT06813911
Recruiting
Phase 3

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled856 locationsNCT07181109
Recruiting
Phase 3

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1155 locationsNCT07064473
Recruiting
Phase 3

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled618 locationsNCT07517263
Recruiting
Phase 3

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Cardiovascular Disease
Amgen11,000 enrolled247 locationsNCT07136012
Recruiting
Phase 3

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Cardiovascular Disease
AstraZeneca15,100 enrolled1333 locationsNCT07000357
Recruiting
Phase 4

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Cardiovascular DiseasesDementiaCognitive Impairment, Mild
Duke University20,000 enrolled103 locationsNCT04262206
Recruiting
Phase 3

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled752 locationsNCT07157774
Recruiting
Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled772 locationsNCT07037433
Recruiting
Phase 1

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

HypercholesterolaemiaMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG90 enrolled18 locationsNCT07491172
Recruiting
Phase 3

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Cardiovascular Disease
Amgen406 enrolled40 locationsNCT07293260
Recruiting
Phase 3

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Cardiovascular RiskAcute Myocardial Infarction (AMI)
Novo Nordisk A/S10,000 enrolled970 locationsNCT06118281
Recruiting
Not Applicable

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

Cardiovascular DiseasesCoronary Artery DiseaseNative Coronary Artery Stenosis
Concept Medical Inc.1,605 enrolled24 locationsNCT06271590